导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -9.71% | 3736/4773 |
| 近一周 | -2.35% | 3760/5465 |
| 近一月 | -2.74% | 1861/5421 |
| 近一季 | 0.66% | 871/5231 |
| 近半年 | -6.76% | 3248/4920 |
| 近一年 | -14.91% | 3689/4394 |
| 近两年 | 34.26% | 2125/2954 |
| 近三年 | 20.90% | 1453/2253 |
| 成立以来 | 2.22% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.56% 4235/4961 |
-8.96% 3934/5312 |
- - |
- - |
| 2025 | 28.73% 1459/4813 |
16.56% 143/3635 |
3.75% 954/4076 |
15.40% 2809/4524 |
-7.76% 3837/4813 |
| 2024 | 12.35% 1250/3463 |
-6.25% 2031/2808 |
4.48% 211/3014 |
20.10% 758/3129 |
-4.50% 2472/3463 |
| 2023 | -14.00% 1576/2656 |
-1.36% 1866/2280 |
-1.61% 506/2385 |
-9.10% 1778/2515 |
-2.51% 484/2655 |
| 2022 | -9.81% 189/2207 |
-10.74% 415/1919 |
7.46% 470/2016 |
-17.92% 1660/2113 |
14.56% 81/2208 |
| 2021 | -14.55% 1149/1822 |
2.88% 208/1255 |
2.30% 1006/1330 |
-12.42% 1307/1466 |
-7.29% 1566/1822 |
| 2020 | 9.19% 845/1250 |
-13.61% 933/1028 |
12.07% 700/1067 |
0.41% 1041/1164 |
12.31% 481/1184 |
| 2019 | 13.16% 711/1092 |
11.41% 710/754 |
0.21% 188/804 |
-5.56% 798/850 |
7.34% 449/918 |
| 2018 | - - |
- - |
- - |
- - |
-7.47% 64/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华安CES港股通ETF VS. 长安沪深300非周期A(740101) |